Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Company
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Number of employees : 76 100 people.
Sales per Business
20192020Delta
Oncology6 793.7135.5%8 461.0039.3% +24.54%
Cardiovascular, Renal & Metabolism5 413.3328.3%5 533.5725.7% +2.22%
Respiratory4 225.7922.1%4 177.4719.4% -1.14%
Other Diseases2 038.8210.7%2 017.389.4% -1.05%
Externalisation Revenue641.983.4%566.932.6% -11.69%
GBP in Million
Sales per region
20192020Delta
United States6 307.7233%6 983.2532.5% +10.71%
China3 815.0420%4 168.1119.4% +9.25%
Japan1 976.8910.3%2 001.799.3% +1.26%
United Kingdom1 428.197.5%1 357.666.3% -4.94%
Other Asia, Africa and Australasia1 111.515.8%1 196.245.6% +7.62%
Other Continental Europe1 011.965.3%1 084.725% +7.19%
Sweden653.743.4%800.093.7% +22.39%
Germany551.842.9%730.693.4% +32.41%
Other Americas638.063.3%593.442.8% -6.99%
France453.072.4%509.222.4% +12.39%
Canada365.281.9%464.772.2% +27.24%
Italy310.411.6%336.101.6% +8.28%
Spain281.411.5%310.371.4% +10.29%
Australia208.511.1%219.911% +5.47%
GBP in Million
Managers
Name Title Age Since
Pascal Soriot Chief Executive Officer & Executive Director 61 2012
Aradhana Sarin Chief Financial Officer & Executive Director 46 2021
Menelas Pangalos EVP-Biopharmaceuticals Research & Development 53 2019
Pam Cheng Executive VP-Operations & Information Technology 49 2015
Henry Cremisi Medical Director - -
Hasan Jafri Senior Medical Director - -
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability - 2017
Marcus Wallenberg Independent Non-Executive Director 64 1999
Leif Johansson Non-Executive Chairman 69 2012
Philip Arthur John Broadley Senior Independent Non-Executive Director 59 2021
Members of the board
Name Title Age Since
Leif Johansson Non-Executive Chairman 69 2012
Marcus Wallenberg Independent Non-Executive Director 64 1999
Pascal Soriot Chief Executive Officer & Executive Director 61 2012
Philip Arthur John Broadley Senior Independent Non-Executive Director 59 2021
Nazneen Rahman, Dr. Independent Non-Executive Director - 2017
Sherilyn McCoy Independent Non-Executive Director 61 2017
Deborah DiSanzo Independent Non-Executive Director 60 2017
Tony Mok, Dr. Independent Non-Executive Director 59 2019
Michel DemarÚ Independent Non-Executive Director 65 2019
Euan A. Ashley, Dr. Non-Executive Director - 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,549,158,964 1,492,933,845 96.4% 0 0.0% 96.4%
Shareholders
NameEquities%
Wellington Management Co. LLP 68,525,329 4.42%
Capital Research & Management Co. (World Investors) 56,102,804 3.62%
BlackRock Investment Management (UK) Ltd. 54,582,684 3.52%
Investor AB (Investment Company) 51,587,810 3.33%
The Vanguard Group, Inc. 43,410,000 2.80%
Norges Bank Investment Management 29,430,000 1.90%
BlackRock Fund Advisors 26,594,541 1.72%
Capital Research & Management Co. (Global Investors) 20,726,848 1.34%
BlackRock Advisors (UK) Ltd. 19,081,467 1.23%
SSgA Funds Management, Inc. 14,043,000 0.91%
Holdings
NameEquities%Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820) 18,750,000 75.0% 753,155,063 USD
ADC THERAPEUTICS SA (ADCT) 4,011,215 5.23% 116,285,123 USD
CIRCASSIA GROUP PLC (CIR) 71,081,217 17.0% 41,896,691 USD
INNATE PHARMA (IPH) 7,485,500 9.48% 41,857,643 USD
SILENCE THERAPEUTICS PLC (SLNCF) 4,397,247 4.90% 30,439,019 USD
PIERIS PHARMACEUTICALS, INC. (PIRS) 3,584,230 5.37% 16,415,773 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS) 3,004,554 6.25% 11,297,123 USD
INOZYME PHARMA, INC. (INZY) 1,109,910 4.69% 10,366,559 USD
ENTASIS THERAPEUTICS HOLDINGS INC. (ETTX) 2,164,855 4.58% 6,169,837 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS) 884,956 7.30% 3,097,346 USD
Markets and indexes
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  AZN
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTRAZENECA PLC13.52%171 528
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ELI LILLY AND COMPANY47.55%225 859
ABBVIE INC.8.18%204 915
MERCK & CO., INC.-9.00%188 031
NOVARTIS AG-11.25%180 565
SANOFI9.07%122 030
BRISTOL-MYERS SQUIBB COMPANY-11.41%121 969
AMGEN INC.-13.50%113 104
GLAXOSMITHKLINE PLC14.84%102 790
CHUGAI PHARMACEUTICAL CO., LTD.-33.40%52 902
JIANGSU HENGRUI MEDICINE CO., LTD.-47.18%50 537
BAYER AG-5.78%50 479
DAIICHI SANKYO COMPANY, LIMITED-19.69%48 101
TAKEDA PHARMACEUTICAL COMPANY LIMITED-19.49%41 547
ASTELLAS PHARMA INC.11.29%28 790
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY44.16%23 918
CATALENT, INC.22.33%21 794